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Abstract
Background: Dyslipoproteinemia, obesity and insulin resistance are integrative constituents of the metabolic syndrome and
are major risk factors for hypertension. The objective of this study was to determine whether hypertension specifically
affects the plasma lipidome independently and differently from the effects induced by obesity and insulin resistance.
Methodology/Principal Findings: We screened the plasma lipidome of 19 men with hypertension and 51 normotensive
male controls by top-down shotgun profiling on a LTQ Orbitrap hybrid mass spectrometer. The analysis encompassed 95
lipid species of 10 major lipid classes. Obesity resulted in generally higher lipid load in blood plasma, while the content of
tri- and diacylglycerols increased dramatically. Insulin resistance, defined by HOMA-IR .3.5 and controlled for BMI, had little
effect on the plasma lipidome. Importantly, we observed that in blood plasma of hypertensive individuals the overall
content of ether lipids decreased. Ether phosphatidylcholines and ether phosphatidylethanolamines, that comprise
arachidonic (20:4) and docosapentaenoic (22:5) fatty acid moieties, were specifically diminished. The content of free
cholesterol also decreased, although conventional clinical lipid homeostasis indices remained unaffected.
Conclusions/Significance: Top-down shotgun lipidomics demonstrated that hypertension is accompanied by specific
reduction of the content of ether lipids and free cholesterol that occurred independently of lipidomic alterations induced by
obesity and insulin resistance. These results may form the basis for novel preventive and dietary strategies alleviating the
severity of hypertension.
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Introduction
Hypertension, a key component of the metabolic syndrome, is a
major risk factor for cardiovascular disease and mortality [1–3].
Population-based studies indicate that the prevalence of hyper-
tension is about 20% in normal weight individuals and more than
50% in obese individuals [4,5]. Hypertension is frequently
accompanied by metabolic disorders such as elevated levels of
triglycerides and LDL cholesterol, lowered levels of HDL
cholesterol, as well as insulin resistance [5]. Early hypertension is
associated with increased epicardial and visceral fat deposits [6,7],
the cells which secrete adipokines modulating both mineralocor-
ticoid secretion and sympathetic nervous activity, thus contribut-
ing to increased blood pressure. Dyslipidemia triggers endothelial
dysfunction further contributing to the development of hyperten-
sion [8]. As lipid-lowering drugs contribute to blood pressure
normalization, treatment with statins might prevent coronary and
stroke events in hypertensive patients who have average or lower
than average levels of blood plasma cholesterol [9,10].
Traditionally, clinicians monitor lipid homeostasis in blood
plasma via integral indices reflecting the cholesterol content (total,
HDL-, LDL-) and total triglycerides, while phenotypic manifes-
tations of obesity are estimated by the body mass index (BMI) and
waist-to-hip ratio (WHR). While obesity strongly impacts all lipid
homeostasis indices, it is unclear whether the plasma lipidome is
altered specifically and independently of other components of the
metabolic syndrome in patients with hypertension, and, if so, what
lipid species or classes might be affected. Although previous
observations indicated that such links might exist, its molecular
basis remains unclear. We therefore hypothesized that systematic
analysis of the blood plasma lipidome at the level of individual
molecular species might help to elucidate such mechanism.
A palette of mass spectrometry-based technologies has been
applied for lipidome profiling. Lipids can be pre-separated by
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spectrometry (LC-MS/MS) by their accurately determined masses
and retention times [11–16]. Alternatively, shotgun lipidomics
relies upon direct infusion of total lipid extract into a tandem mass
spectrometer. Species of individual lipid classes are detected and
quantified using precursor and neutral loss scans specific for their
common structural elements [17–20]. Top-down shotgun strategy
takes advantage of high mass resolution of modern mass
spectrometers, such that lipids of major classes could be recognized
by accurately determined precursor masses with no recourse to
MS/MS. Although individual molecular species are not identified
directly, as by complementary bottom-up lipidomics [21–23], top-
down lipidomics has demonstrated potential in high-throughput
screens [24].
Lipidomics screening of plasma in a small cohort of monozy-
gotic twins discordant for obesity revealed a significant increase in
lysophosphatidylcholines (LPC) and a decrease in ether phospho-
lipids in obese individuals [25]. Predictably, gradual weight loss
decreased the overall level of serum triacylglycerols (TAG) [26].
The improvement of insulin sensitivity during diet-induced weight
loss was also accompanied by diminishing the levels of phospha-
tidylcholines (PC) and phosphatidylethanolamines (PE), while the
levels of LPC’s and sphingomyelines (SM) remained unchanged
[26]. Whether hypertension is associated with characteristic
plasma lipidomic changes has not yet been investigated.
A case-controlled study was designed to address the interrela-
tionship between hypertension and blood plasma lipidome. Valid
population sampling was achieved by the random recruitment of
individuals from an ongoing prospective study and by the
enforcement of strict exclusion criteria, such as on-going treatment
with antihypertensive drugs, indications of inflammatory process-
es, liver and kidney diseases, as well as diabetes mellitus. The
impact of variable genetic and hormonal background was
addressed as follows: first, by engaging a larger subject population;
second, by restricting the study to men; and third, by accounting
for the lipidomic impact of known potent hypertension-related
factors, such as obesity and insulin resistance and considering these
factors as covariates in multivariate (MANOVA) and univariate
(ANCOVA) models of analysis of variance.
The top-down lipidomics approach monitored the abundance
of 95 lipid species originating from 10 lipid classes in the plasma of
70 male individuals, 19 of whom were hypertensive. We were able
to demonstrate that hypertension was specifically associated with
reduced levels of free plasma cholesterol and ether lipids, in
particular with ether phosphatidylcholines (PC-O) and ether
phosphatidylethanolamines (PE-O), while other lipid classes
(including TAGs) remained practically unaffected.
Materials and Methods
Subjects
Male subjects were randomly selected from the ongoing
PRAEDIAS prevention study in the Department of Internal
Medicine III at Carl Gustav Carus Medical School, Technical
University Dresden as previously described [27]. Each participant
provided written informed consent and the study was approved by
the Dresden Ethics Committee (EK139092001) in accordance
with the Declaration of Helsinki principles. All test subjects
underwent a standardised clinical examination including a
comprehensive metabolic characterization. Only individuals who
did not manifest acute inflammatory processes (C-reactive protein
,5 mg/L), diabetes mellitus or severe renal or hepatic diseases,
participated in the study. Subjects should not have received
antihypertensive medication or therapy that might have affected
lipid metabolism. The study population consisted of 70 men
including 19 subjects with hypertension. Basal anthropometric and
clinical data are presented in Supplemental Table S1 (Supple-
mentary Materials).
Blood samples for lipid profiling were taken after overnight
fasting and EDTA-plasma was prepared by 10 min centrifugation
at 4uC and 3000 g. All samples were immediately shock-frozen in
liquid nitrogen and stored at 280uC until analysed.
Homeostasis model assessment of insulin resistance (HOMA-IR)
index was calculated as (fasting insulin [mU/mL]6fasting glucose
[mM])/22.5 [28].
Blood pressure was measured in accordance with WHO
guidelines. The diagnosis of hypertension was based on systolic
blood pressure $140 mmHg and/or diastolic blood pressure
90$mmHg.
Clinical chemistry indices
Plasma triglycerides, total cholesterol, HDL and LDL choles-
terol were determined by standard enzymatic methods on a
MODULAR analyser (Roche, Indianapolis, IN), free fatty acid on
a COBAS MIRA analyser (Global Medical Instrumentation Inc,
Ramsey, MN), and plasma glucose on a DX80 analyser (Beckman-
Coulter, Fullerton, CA). HbA1C was measured by HPLC (Bio-
Rad Laboratories, Richmond, CA). Plasma insulin levels were
determined by an enzyme-linked immunosorbent assay (Asbach
Medical Products, Obrigheim, Germany).
Chemicals and lipid standards
Synthetic lipid standards were purchased from Avanti Polar
Lipids, Inc. (Alabaster, AL). Water (LC-MS grade) was purchased
from Fisher Scientific (Loughborough, United Kingdom); chloro-
form, methanol and ammonium acetate were of Liquid Chroma-
tography grade and purchased from Fluka (Buchs SG, Switzer-
land). Methyl-tert-butylether (MTBE) and 2-propanol were
purchased from Sigma-Aldrich Chemie GmbH (Munich, Ger-
many).
Lipid extraction
Plasma samples were thawed and extracted with MTBE as
described in [20]. Briefly, 20 mL of EDTA plasma was placed in a
2 mL vial (Eppendorf, Hamburg, Germany). 320 mL of the
internal standards mixture consisting of 1,2-di-O-octadecyl-sn-
glycero-3-phosphocholine, 1,2-di-O-phytanyl-sn-glycero-3-phos-
phoethanolamine and N-heptadecanoyl-D-erythro-sphingosylpho-
sphorylcholine with a concentration of 3.2 nM for each lipid in
94% methanol was added and the solution was thoroughly mixed.
Afterwards, 1 mL of MTBE was added and the mixture was
vortexed at 20uC for one hour. Then 250 mL of water were added
and tube thoroughly vortexed. After centrifuging for 1 minute at
4000 rpm on a Minispin centrifuge (Eppendorf, Hamburg,
Germany,) 800 mL of the upper organic phase was transferred
into a new vial and stored at 220uC until analysis. For mass
spectrometric analysis, 8 mL of the extract were diluted with 80 mL
CHCl3/MeOH/2-propanol 1/2/4 (v/v/v) containing 7.5 mM
ammonium acetate in a well of a 96 well plate (Eppendorf,
Hamburg, Germany) and then sealed with aluminum foil.
Mass spectrometric analysis
Mass spectrometric analysis was performed on a hybrid LTQ
Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen,
Germany) equipped with a robotic nanoflow ion source TriVersa
(Advion BioSciences Ltd, Ithaca NY) using chips with 4.1 mm
nozzle diameter. The ion source was controlled by Chipsoft 6.4.
Lipidomics in Hypertension
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voltage of 0.95 kV and gas pressure 1.25 psi. Plates with lipid
extracts were chilled down to 12uC.
MS survey scans were acquired in positive ion mode using the
Orbitrap analyzer operated under the target mass resolution of
100,000 (Full Width at Half Maximum, FWHM), defined at m/z
400 under automatic gain control set to 1.0610
6 as the target
value [24]. Where specified, targeted MS
n experiments were
performed using collision-induced dissociation (CID) mode using
the linear ion trap analyzer of the LTQ Orbitrap machine [24,29].
Data pre-processing and identification of lipids species
Raw data files acquired from analyzed samples were converted
into *.mzXML format by readw.exe utility (a tool of Trans-
Proteomic Pipeline software collection, downloaded from http://
tools.proteomecenter.org/wiki/index.php?title=Software:ReAdW).
Mass spectra were further processed by LipidX software developed
in-house. Altogether, the data set consisted of 151 high-resolution
survey mass spectra including 12 blank controls. Spectra acquired
within 28 s to 120 s from the start of sample infusion (timing
required to stabilize the analyte flow and electrospray, as was
judged by total ion current (TIC) trace) were averaged and
recalibrated using m/z of synthetic standards SM 35:1 and PC –O
20:0/-O 20:0 as references. Recalibrated spectra were further
aligned such that related peaks were matched within the full
dataset. Only peaks detected at the signal-to-noise ratio above the
factor of 5 and recognized in more than 20% of all spectra were
further considered. Identification of lipid species relied on
accurately determined masses [24] considering a mass accuracy
of better than 4 ppm and a retrieval rate of 90% for all plasma
samples. Peaks also recognized in blank controls were excluded.
Lipidomics analysis covered 10 major lipid classes: cholesterol
(Chol), cholesterylesters (Chol-FA), phosphatidylcholines (PC, PC-
O), lysophosphatidylcholines (LPC), phosphatidylethanolamines
(PE, PE-O), sphingomyelins (SM), diacylglycerols (DAG) and
triacylglycerols (TAG).
Lipid Quantification
Species of PC, PC-O and LPC were quantified by the intensity
ratios of their peaks to the internal standard PC-O 18:0/-O 18:0;
PE and PE-O species – to the internal standard PE-O 20:0/-O
20:0; SM species – to the internal standard SM 35:1. The
abundance of individual TAG, DAG and Chol-FA species was
determined by dividing their absolute intensities with the average
of the absolute intensities of the three internal standards.
The abundance of free cholesterol was determined from the
intensity of the positively charged ammonium adduct at m/z
404.3892. As an integrated abundance measure of cholesteryl
esters, we considered the intensity of the peak with m/z 369.3521
(Chol- moieties). This fragment is produced in the ion source from
ammonium adducts of cholesteryl esters via neutral loss of acyl
chains [18].
Statistical analysis
Two-tailed bivariate Pearson correlation tests were applied to
evaluate the correlation between plasma levels of total cholesterol
and triglycerides as measured by routine clinical chemistry
methods and sums of plasma levels of cholesterol and triglyceride
species obtained by mass spectrometry.
To obtain a multivariate preliminary data survey a ‘‘Principal
Component Analysis’’ of all 95 lipid species and Chol-moieties
integral index was performed in order to assemble highly
correlated lipid species into common factors. Using ‘‘Eigenvalues’’
over 3 and ‘‘Varimax’’ rotation with Kaiser Normalization five
factors were extracted. Factor composition is shown in Supple-
mental Table S3. The association between lipidomic profile and
hypertension was subsequently examined using a model of
multivariate analysis of variance (MANOVA) with these factors
as dependent variables and hypertension status as an independent
factor, thereby regarding BMI and HOMA as covariates. The
specific effect of each factor on hypertension status was then tested
by univariate analysis of variance (ANCOVA) with p-values
corrected for multiple testing (Bonferroni procedure).
In order to assess the impact of BMI and HOMA-IR on the
plasma lipid profile of the study population, cut-offs for maximal
discrimination of two groups were calculated by repeated
discriminant function analysis using triglyceride species as
discriminating variables. The resulting cutoffs were 27.5 kg/m
2
for BMI (60
th percentile; 87.1% correct classification), and 3.5 for
HOMA-IR (67
th percentile; 80.0% correct classification).
For comparisons among groups (insulin-sensitive vs. insulin-
resistant and normotensive vs. hypertensive) a general linear model
was applied with lipid species as dependent variables and HOMA
or the hypertension status as fixed factor. Since most of the lipid
species were correlated (by bivariate correlation analysis) to BMI,
this parameter was used as covariate in both models evaluating the
effects of insulin resistance and hypertension on lipid species.
Additionally, HOMA was used as a covariate in the model
calculating the effect of hypertension on lipid profile. Adjusted
means of lipid species were taken from both models for further
calculations.
Data are given as mean percentage changes or as mean with a
95% interval of confidence unless otherwise stated. A value of
p,0.05 was considered statistically significant. All statistical
analyses were performed with the SPSS statistical package
(v.16.0 for Windows; SPSS, Chicago, IL, USA).
Results
Clinical characteristics of the study population
Basal clinical data show that men with hypertension had
significantly higher BMI, WHR, fasting plasma glucose and
HOMA (Table 1). The prevalence of hypertension was 16.7% (7/
42) in lean and 42.9% (12/28) in obese men. Conversely, the
prevalence of obesity (BMI.27.5 kg/m
2) was 63.2% (12/19) in
the hypertensive and 31.4% (16/51) in the control group (Figure 1).
Furthermore, 47.4% (9/19) of the hypertensive group had a
HOMA-IR index .3.5, whereby 8 were obese (Figure 1). In
comparison, the prevalence of insulin resistance in the control
group was 27.5% (14/51), including 11 obese individuals
(Figure 1). Cumulatively, these data confirm an increased
prevalence of obesity and insulin resistance in patients with
hypertension, which were associated with significantly higher
plasma triglyceride levels (Table 1). These differences disappeared
after controlling the triglyceride values for BMI and HOMA.
Shotgun screening of the plasma lipidome
A top-down shotgun lipidomics workflow [24] was optimized for
high-throughput clinical screens (Figure 2). Internal standards
were spiked into plasma samples prior to one-step lipid extraction
by MTBE. Total lipid extracts were directly infused into a LTQ
Orbitrap mass spectrometer and survey mass spectra acquired
within less than 3 min time at the target mass resolution of
100,000 (FWHM). High mass resolution, better than 4 ppm mass
accuracy and practical compositional constraints identified lipid
species directly, solely relying on their accurately determined m/z
[19,24]. Each plasma sample was analyzed with 2 technical
(independent analysis of the same extract) replicas. The dataset,
Lipidomics in Hypertension
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comprised 151 survey mass spectra acquired from 70 individual
plasma samples. Within the imposed compositional constraints,
LipidX quantified 95 lipids from 10 major classes: 5 lipids
belonging to Chol-FA, 4 to DAGs, 5 to LPCs, 13 to PCs and 13 to
PC-Os, 8 to PEs and 5 to PE-Os, 10 to SMs, 31 to TAGs, and free
cholesterol. The total quantities of TAGs and cholesterol
determined by mass spectrometry were strongly correlated with
clinical indices (Figure 3).
Principal component analysis (PCA) of the plasma
lipidome
Multiple correlations of individual lipid species were analyzed
by the method of PCA. Highly correlated lipid species were
assembled into five common factors with Eigenvalues over 3
(Supplemental Table S3). Factor 1 included PCs, LPCs, and
TAGs with short saturated fatty acid moieties; Factor 2 included
all PC-O and PE-O species except PE-O [40:5]; Factor 3 mostly
included TAGs with polyunsaturated fatty acid moieties; Factor 4
mainly included SMs and cholesterol esters; Factor 5 mainly
included TAGs and DAGs with unsaturated fatty acid moieties
(Supplemental Table S3). The individual regression coefficients of
these factors were saved and used as dependent variables in a
model of multivariate analysis of variance (MANOVA).
Both obesity and insulin resistance affect plasma
lipidome
Based on clinical chemistry data obese individuals had
significantly higher triglycerides and lower HDL-cholesterol,
whereas LDL- and total cholesterol remained unchanged
(Figure 4A). Corroborating these findings, lipidomics analysis
revealed that the abundance of nearly all lipids classes was
generally increased (Figure 4B) in obese subjects. The content of
saturated TAG and DAG species (Figure 4B) having, on average,
less than one double bond per fatty acid moiety, increased 2- to 3-
fold.
According to clinical indices, individuals with insulin resistance
(HOMA-IR .3.5) had a significant decrease in HDL-cholesterol,
while changes in triglycerides and total cholesterol were insignif-
icant (Figure 5A). The lipidomic screen (Figure 5B), controlled for
the effects of BMI, revealed a pattern of predominantly decreased
levels of LPC, PC, PC-O, PE, and SM, reaching significance only
for PE 38:2 species. There was also a clear trend toward increasing
the content of PE-O species, while the content of TAGs varied
Table 1. Basal anthropometric and clinical data in normotensive and hypertensive men.
Normotensives n=51 Hypertensives n=19 Significance p=
Age mean 51.7 57.3 0.173
[years] 95% CI 47.3–56.1 50.8–63.9
BMI mean 25.6 27.8 0.012
[kg/m
2] 95% CI 24.7–26.5 26.3–29.3
WHR mean 0.92 0.96 0.036
95% CI 0.90–0.94 0.92–0.99
RR systolic mean 125 154 ,0.001
[mmHg] 95% CI 122–128 149–160
RR diastolic mean 72 85 ,0.001
[mmHg] 95% CI 70–75 77–93
Triglycerides mean 1.28 1.65 0.036
[mM] 95% CI 1.13–1.43 1.24–2.06
Total cholesterol mean 5.11 5.20 0.691
[mM] 95% CI 4.89–5.34 4.79–5.62
HDL-cholesterol mean 1.53 1.48 0.614
[mM] 95% CI 1.42–1.63 1.32–1.63
LDL-cholesterol mean 3.31 3.30 0.945
[mM] 95% CI 3.09–3.53 2.81–3.78
Free fatty acids mean 0.46 0.54 0.105
[mM] 95% CI 0.41–0.52 0.47–0.61
HbA1C mean 5.4 5.6 0.299
[%] 95% CI 5.2–5.6 5.4–5.8
Glucose mean 5.3 5.6 0.037
[mM] 95% CI 5.1–5.5 5.3–6.0
Insulin mean 82 107 0.054
[pM] 95% CI 71–93 76–138
HOMA mean 2.87 3.91 0.035
95% CI 2.43–3.30 2.77–5.05
Statistical analyses by univariate analyses of variance.
doi:10.1371/journal.pone.0006261.t001
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insulin resistance is accompanied by specific, but minor changes of
the lipidome, which might be partially concealed by the effects if
obesity.
Altogether, shotgun lipidomics revealed that in the investigated
cohort obesity and insulin resistance affect the lipidome in different
ways. Since obesity-related changes are massive, special statistical
considerations should be taken to reveal the effects of concomitant
metabolic disorders.
Hypertension and plasma lipidome
Contrary to the effect of BMI both clinical indices and shotgun
profiling did not reveal major differences in plasma lipidome of
normotensive and hypertensive subjects (Figure 6A and B), while
changes of moderate magnitude that were observed among almost
all lipid classes. The most notable exception, however, was a
statistically confident and coherent decrease in the content of free
cholesterol and PC-O species (Figures 6 and 7). Interestingly, the
PE-O content was also decreased (significantly for the three out of
five detected species, Figures 6 and 7), while PE and PC remained
almost unchanged – which is, again, in sharp contrast to
lipidomics changes instigated by BMI increase. Therefore, we
concluded that hypertension is specifically associated with the
deficiency of free cholesterol, PC-O, and PE-O species in male
plasma lipidomes and it is seemingly unrelated to obesity-
dependent alterations.
A multivariate model (MANOVA) comprising PCA factors as
dependent variables, hypertension status as independent factor,
and BMI and HOMA as covariates indicated significant and
independent effects of BMI (p, 0.001) and hypertension status
(p=0.032). The subsequent univariate analysis with p-values
corrected for multiple tests (Bonferroni procedure) appointed to
the significant difference between normotensive and hypertensive
individuals for Factor 2 (p=0.018), which emphasized the role of
ether lipids in the pathogenesis of hypertension.
Further, structural analysis of these PC-Os using with MS
3 in
the negative ion mode [30] revealed that all affected highly
unsaturated species, such as PC-O 36:4, PC-O 38:5, PC-O 36:5,
PC-O 38:4 and PC-O 38:6 comprised the arachidonic acid moiety
(Supplemental Table S2). We further determined that PC-O
species were present in the concentration of approx. 32.2 mM
(individual concentrations ranging from 9.6 to 64.8 mM) in the
whole studied population. Individuals with hypertension had
significantly lower levels of these PC-O species than normotensive
controls (26.262.8 vs. 34.461.7 mM, p=0.014). Structural
analysis of downregulated PE-O species by MS
2 in positive ion
mode [31] revealed that these species were plasmalogens with high
content of arachidonic acid moieties (Supplemental Table S2).
Discussion
Hypertension, as an integral constituent of the metabolic
syndrome, is frequently accompanied by obesity and insulin
Figure 1. The study population. The structure of patient cohort is presented with respect to hypertension, obesity and insulin resistance. Bars
represent the total number of patients (n=70); horizontal dotted lines stand for the thresholds for blood pressure, BMI and HOMA-IR, respectively.
Numbers within each bar indicate the number of patients within each of the sub-groups having the corresponding indices above or below the
thresholds. For example, among hypertensive patients (n=19; the bar at the left hand side), 7 were not obese (BMI,27.5 kg/m
2; the bar in the
middle) and 6 of those showed normal insulin resistance (HOMA-IR ,3.5; the bar at the right hand side).
doi:10.1371/journal.pone.0006261.g001
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metabolism [4,5,25,26]. The analysis of the plasma lipidome by
top-down shotgun mass spectrometry revealed that obesity
increased the content of in Chol-FA, PC, PE, PE-O, and LPC
species. Considering these changes in a model of univariate
analysis of variance, we showed that hypertension was specifically
associated with diminished free cholesterol and ether lipids levels
that were statistically significant for eight PC-O and three PE-O
species, in which arachidonic acid was the most abundant fatty
acid moiety. It is therefore conceivable that the deficiency of
arachidonic acid-rich ether lipids may substantially contribute to
the pathogenesis of essential hypertension.
It is known that lipid concentrations in circulating blood show
considerable gender-related differences. In premenopausal women
total cholesterol, LDL-cholesterol and triacylglycerol concentra-
tions are lower and HDL-cholesterol concentrations are higher
than in men [32]. With age and menopausal transition, a profound
shift in lipid profile occurs, which is characterized by an increase of
LDL-cholesterol and triglycerides and a decrease in HDL-
cholesterol. Sex hormone-induced effects on lipid profile may
superpose and conceal pathogenetically relevant changes in
lipidomic profiles. Therefore the subject selection of this study at
this stage was restricted to men.
The association between BMI, insulin resistance, and hyper-
tension was previously established [33]. Individuals with insulin
resistance have a higher risk of developing hypertension [3].
Lipidomic profiles in the affected individuals are altered by BMI
and insulin resistance [25]. In this study, individuals with
hypertension had significantly higher values for BMI and
HOMA-IR. Therefore, the effects of BMI and HOMA-IR on
lipidomic profile were analyzed for the entire study population.
Corroborating the evidence provided by Pietilainen et al [25], we
observed that in individuals with a BMI .27.5 kg/m
2 the content
of almost all detectable TAG and DAG species increased, along
with several Chol-FA, PCs, PEs, and LPCs. Additionally, the
content of two PE-O species was significantly increased.
Conversely, the group of individuals with insulin resistance
(HOMA-IR .3.5) revealed a specific decrease in the abundance
of PE 38:2 species and the general tendency to diminished content
of LPC, PC, PC-O, PE, SM, and PE-O species.
These alterations in lipid metabolism induced by increased fat
cell mass and/or insulin resistance are likely to contribute to the
development of the cardiovascular complications of the metabolic
syndrome [3]. Elevations in inflammatory lipids such as LPC and
long-chain fatty acids will induce endothelial dysfunction and
eventually lead to hypertension [34]. Alterations in insulin
Figure 2. The workflow for top-down shogun lipidomic screens. A) EDTA plasma samples of 70 men (age of 22–79) was collected and lipids
were extracted by methyl-tert-bytyl ether. Total extracts reconstituted in CHCl3/MeOH/2-propanol 1/2/4 (v/v/v) mixture, containing 7.5 mM
ammonium acetate were directly infused into a LTQ Orbitrap mass spectrometer and high resolution mass spectra were acquired. 151 mass spectra
were analyzed using LipidX software, which identified and quantified individual lipids. B) Representative high resolution mass spectrum of a total
lipid extract of blood plasma. Spectra acquisition time was 3 min, while full sample analysis time was less than 4 min. Most abundant peaks are
annotated with m/z; shaded areas designate m/z ranges in which corresponding lipid classes were detected. Major background peaks are designated
with asterisks.
doi:10.1371/journal.pone.0006261.g002
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amines induced by these lipid changes will likewise affect blood
pressure regulation [35–37].
A particular challenge in this study was to differentiate the r
interrelationship of hypertension and lipid metabolism from
concomitant effects of obesity and insulin resistance. Therefore,
all quantities for lipid species were controlled for BMI and
HOMA-IR using them as covariates in a general linear univariate
model of variance (ANCOVA). This approach revealed a
significant decrease of most of the analysed PC-O and PE-O
lipids in individuals with hypertension, which was subsequently
corroborated by direct absolute quantification of corresponding
PC-O species.
Although a role for PC as major structural lipids of the cell
membrane is well established, it is as yet unclear whether PC-O
play any direct role in blood pressure control as has been
Figure 3. Quantification by top-down lipidomics correlates with clinical indices. A) Linear regression analysis of the total cholesterol
content determined by mass spectrometry and by clinical chemistry analysis. Mass spectrometry quantified total cholesterol content by summing up
the abundances of free cholesterol, all cholesteryl esters and their common fragment ion at m/z 369.35. B) Linear regression of the total triglyceride
content determined by mass spectrometry and by clinical chemistry analysis. Mass spectrometry quantified the total TAG content by summing up all
the abundances of individual TAG species. In both panels each dot represents the total extract of individual plasma sample.
doi:10.1371/journal.pone.0006261.g003
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2 (n=28) relative to a
control group of men with BMI#27.5 kg/m
2 (n=42), as determined by clinical indices (panel A) and by top-down shotgun mass spectrometry (panel
B). In B relative % was determined for each species individually, irrespective of its absolute abundance. In the diagram, within each lipid class, species
were sorted according to their absolute abundance from top to bottom in descending order. For example, among the TAG class the species TAG
[52:2] was the most abundant, while TAG [49:2] was the least abundant. Data are presented as mean. Statistical analysis was performed by univariate
analysis of variance.
doi:10.1371/journal.pone.0006261.g004
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6261Figure 5. The effectofinsulin resistance on plasma lipidome. Changes in plasma lipidome of men withHOMA-IR.3.5 (n=23), relative toa control
group of men with HOMA-IR#3.5 (n=47), as determined by clinical chemistry indices (panel A) and by top-down shotgun mass spectrometry (panel B).
Statistical analysis by univariate analyses of variance with mean data controlled for BMI (ANCOVA) as described in Materials and Methods section.
doi:10.1371/journal.pone.0006261.g005
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PLoS ONE | www.plosone.org 9 July 2009 | Volume 4 | Issue 7 | e6261Figure 6. The effect of hypertension on plasma lipidome. Changes in plasma lipidome of men with hypertension (n=19), relative to a control
group of men without hypertension (n=51), as determined by clinical indices (panel A) and by top-down shotgun mass spectrometry (panel B).
Statistical analyses by univariate analyses of variance with mean data controlled for BMI and HOMA-IR (ANCOVA) as described in Material- and
Methods section.
doi:10.1371/journal.pone.0006261.g006
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factors (PAFs) [38,39].
We emphasise that PC-Os identified in this screen are not PAFs
as they harbour a fatty acid moiety at the sn-2 position instead of
the acetyl moiety (Supplemental Table S2). The possibility
remains that decreased abundances of PC-O and PE-O species
reflect some enzymatic deficiency within the PAF biosynthesis
pathway. In particular, lysophosphatidylcholine acyltransferase 2
(LPCAT2) is active in biosynthesis of both PC-Os and PAFs [40]
and it is possible that observed changes in PC-Os are more
pronounced because of their high stability and abundance in blood
plasma, compared to PAFs.
Further structural characterization of PC-O and PE-O species
revealed that the major molecular species were plasmalogens.
Although Maeba et al. [41] reported reduced serum levels of
plasmalogens in patients with abnormal glucose tolerance and
coronary stenosis, their role in blood pressure regulation remains
unknown.
Importantly, the affected PC-Os (36:4, 38:5, 36:5, 38:4) and PE-
Os (38:5, 38:6, 40:5) species are highly unsaturated and comprise
arachidonic acid as a major fatty acid moiety. It is, however,
unclear if their reduced content impacts on the activity of
arachidonic acid metabolites, like prostaglandins (I2,E 2) and
epoxyeicosatrienoic acids (EET’s), which play critical roles in the
regulation of vascular tone [42–44], or reflects a masked deficit of
arachidonic acid.
Free cholesterol residing in atherosclerotic plaques is an
important factor leading to lesion instability [45], while its role
in plasma remains unclear. Free plasma cholesterol was found in
different lipoprotein particles (HDL, LDL, VLDL) [46]. However,
the decrease of free plasma cholesterol in individuals with
hypertension in our study was obviously not the result of changes
in lipoproteins since the concentrations of HDL- and LDL-
cholesterol did not differ between the groups. One possible
explanation might be an increased activity of the lecithin:choles-
terol acyltransferase (LCAT) in patients with hypertension. This
suggestion is an accordance with the report from Dullaart et al.
[47], which described increased LCAT activity in patients with
metabolic syndrome.
Three important conclusions could be drawn from this study.
First, top-down shotgun lipidomics established itself as a novel
technology allowing high throughput clinical screens. Secondly,
quantitative profiles of the blood plasma lipidome correlated well
with clinical lipid homeostasis indices. Yet, they provide far more
systematic and accurate description of metabolic disorders. Finally,
this is the first study demonstrating a specific association between
hypertension and lipid profiles. These results may form the basis
for novel dietary strategies for the treatment of the metabolic
syndrome and hypertension.
Supporting Information
Table S1 Basal anthropometric and clinical data of the
investigated population
Found at: doi:10.1371/journal.pone.0006261.s001 (0.05 MB
DOC)
Figure 7. The effect of hypertension on selected species in the blood plasma lipidome. Box plots diagrams of plasma concentrations of
free cholesterol, PC-O [36:4], PC-O [38:4], PE-O [38:5], PE-O [38:6], and PE-O [40:5] in a group of men with hypertension (n=19) and a control group of
men without hypertension (n=51) determined by top-down shotgun mass spectrometry. Statistical analyses by univariate analyses of variance. *
p#0.05, ** p#0.01.
doi:10.1371/journal.pone.0006261.g007
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decreased abundance in subjects with hypertension
Found at: doi:10.1371/journal.pone.0006261.s002 (0.04 MB
DOC)
Table S3 Principal component analysis of 95 lipid species and
Chol-moieties integral index identified in blood plasma by mass
spectrometry
Found at: doi:10.1371/journal.pone.0006261.s003 (0.08 MB
DOC)
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